431 studies found for:    Waldenstrom
Show Display Options
Rank Status Study
1 Completed
Has Results
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Perifosine
2 Active, not recruiting LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: LBH589
3 Completed Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Conditions: Waldenstrom's Macroglobulinemia;   Lymphoplasmacytic Lymphoma
Intervention: Drug: Bortezomib (Velcade)
4 Completed Sildenafil Citrate in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Sildenafil citrate (Viagra)
5 Completed Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: BORTEZOMIB
6 Completed Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: Thalidomide
7 Recruiting Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Intervention: Biological: Blood or bone marrow samples
8 Active, not recruiting Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Bortezomib;   Drug: Rituximab
9 Active, not recruiting An Open-label, Phase 1b/2 Study of ACP 196 in Subjects With Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia (WM)
Intervention: Drug: ACP-196
10 Terminated Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: Epratuzumab (hLL2- anti-CD22 humanized antibody)
11 Active, not recruiting Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
Condition: Waldenström's Macroglobulinemia
Interventions: Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab
12 Completed Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia
Conditions: Lymphoplasmacytic Lymphoma;   Waldenstrom's Macroglobulinemia
Intervention: Drug: Campath-1H
13 Terminated
Has Results
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: CC-5103 (lenalidomide);   Drug: Rituximab
14 Active, not recruiting Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: Revlimid
15 Recruiting Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: IMO-8400
16 Active, not recruiting Randomised Trial in Waldenstrom's Macroglobulinaemia
Condition: Waldenstrom's Macroglobulinaemia
Interventions: Drug: Bortezomib;   Drug: Cyclophosphamide;   Biological: Rituximab;   Drug: Fludarabine
17 Completed
Has Results
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinaemia
Intervention: Biological: Ofatumumab
18 Recruiting Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: ABT199
19 Suspended Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: GS-1101
20 Unknown  A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
Condition: Symptomatic Waldenstroms Macroglobulinaemia
Intervention: Drug: Belimumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years